RWLK REWALK ROBOTICS LTD

ReWalk Robotics Presents on Personal Exoskeleton Pricing at Medicare Public Meeting

ReWalk Robotics Presents on Personal Exoskeleton Pricing at Medicare Public Meeting

ReWalk supports “gap-filling” pricing method proposed by CMS with use of up-to-date pricing information.

MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILLIT, Israel, Nov. 30, 2023 (GLOBE NEWSWIRE) -- ReWalk Robotics, Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company"), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, presented at the Healthcare Common Procedure Coding System (“HCPCS”) public meeting on November 29, 2023 and provided feedback to the Centers for Medicare & Medicaid Services (“CMS”) regarding the preliminary payment determination for the code describing the ReWalk Personal Exoskeleton.

“Yesterday’s meeting was an opportunity for us to show our appreciation for the significant progress that CMS has made in providing a pathway for paralyzed individuals to access life-changing exoskeleton technologies,” said Larry Jasinski, CEO of ReWalk. “It was also an opportunity to provide updated pricing information for the current ReWalk Personal Exoskeleton so that CMS can utilize these data in its payment calculations in place of the 2020 data that were used in the preliminary payment determination.”

The meeting was attended by multiple representatives from CMS who had the opportunity to ask questions and seek further clarification on the materials presented. Following this public meeting, CMS is expected to review the additional information submitted by ReWalk and any other commenters, issue a final payment determination in February 2024, and implement payment rate updates to its fee schedule effective April 1, 2024.

About ReWalk Robotics Ltd.

ReWalk Robotics Ltd. is a medical device company that designs, develops, and commercializes innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions. ReWalk’s mission is to fundamentally change the quality of life for these individuals through the creation and development of market leading technologies. Through its recent acquisition of AlterG, Inc., ReWalk has added anti-gravity systems to its growing portfolio of products. Founded in 2001, ReWalk has operations in the United States, Israel, and Germany. For more information on the ReWalk systems, please visit . For more information on the AlterG systems, please visit .

ReWalk® and ReStore® are registered trademarks of ReWalk Robotics Ltd. in the United States and other jurisdictions. AlterG® is a registered trademark of AlterG, Inc. in the United States and other jurisdictions.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Such forward-looking statements may include projections regarding ReWalk's future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk's control. Important factors that could cause ReWalk's actual results to differ materially from those indicated in the forward-looking statements are more fully discussed in ReWalk’s periodic filings with the Securities and Exchange Commission (“SEC”), including the risk factors described under the heading "Risk Factors" in ReWalk's annual report on Form 10-K and 10-K/A for the year ended December 31, 2022 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk's actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

ReWalk Media Relations:

LifeSci Communications

E:

ReWalk Investor Contact:

Mike Lawless

Chief Financial Officer

ReWalk Robotics Ltd

E: 



EN
30/11/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on REWALK ROBOTICS LTD

 PRESS RELEASE

Lifeward Broadens Reimbursement Coverage for ReWalk 7 Personal Robotic...

Lifeward Broadens Reimbursement Coverage for ReWalk 7 Personal Robotic Exoskeleton as Humana Medicare Advantage Plan Issues Prior Authorization Approval Humana and UnitedHealthcare, which granted authorization in November, are the two largest Medicare Advantage providers in the U.S., accounting for  of all Medicare Advantage enrollees This latest approval will help enhance timely access to cutting-edge personal exoskeleton solutions for individuals with spinal cord injury Reimbursement coverage is expected to give Lifeward stronger revenue and cash flow dynamics to scale growth MARLBORO...

 PRESS RELEASE

UnitedHealthcare Medicare Advantage Plan Issues Prior Authorization Ap...

UnitedHealthcare Medicare Advantage Plan Issues Prior Authorization Approval for a ReWalk 7 Personal Exoskeleton Approval marks continued progress in expanding reimbursement pathways and accelerating access to advanced personal exoskeleton technology for individuals with spinal cord injury. MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, announced today that it received it...

 PRESS RELEASE

Lifeward Ltd. Reports Third Quarter 2025 Financial Results

Lifeward Ltd. Reports Third Quarter 2025 Financial Results Record quarter of ReWalk systems placed for Medicare beneficiaries since fee schedule established  Ongoing efficiency initiatives drive 16% year-over-year decrease in quarterly cash burn and 27% decrease in quarterly Non-GAAP operating loss Entered into $3.0 million loan agreement with Oramed Ltd. providing additional capital support MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to tr...

 PRESS RELEASE

Lifeward to Report Third Quarter Financial Results on November 14, 202...

Lifeward to Report Third Quarter Financial Results on November 14, 2025 MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its third quarter 2025 financial results before the markets open on Friday, November 14, 2025. Mark Grant, President and Chief Executive Officer, and Almog Adar, Chief Financial Officer, will host a conference c...

 PRESS RELEASE

First Commercial Medicare Advantage Plan Provides Payment for ReWalk 7...

First Commercial Medicare Advantage Plan Provides Payment for ReWalk 7 Personal Exoskeleton Medicare Advantage claim processed in less than thirty days Additional progress with traditional Medicare claim approvals has accelerated timelines to payment in 2025 MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, announced today that it received its first payment from a commercia...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch